CRSP
CRISPR Therapeutics AG
There isn't enough reported data to score CRSP yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CRSP Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
CRSP's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRSP PE Valuation
CRSP has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CRSP Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect CRSP's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CRSP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.69 | +$0.87 |
| Q2 2026 | -$4.71 | +$0.69 |
| Q1 2026 | -$6.17 | -$1.68 |
| Q4 2025 | -$6.47 | -$2.13 |
| Q3 2025 | -$5.56 | -$2.75 |
| Q2 2025 | -$5.40 | -$2.19 |
| Q1 2025 | -$4.49 | -$1.79 |
| Q4 2024 | -$4.34 | -$2.40 |
CRSP is still losing money, but less than at its worst: $4.69 per share over the past year, against $8.52 at its worst in late 2022.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CRSP on earnings quality, reporting a profit while its opponent remains loss making.
CRSP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $12.7M | +1325% |
| Q2 2026 | $10.2M | +1041% |
| Q1 2026 | $1.5M | +69% |
| Q4 2025 | $864K | -98% |
| Q3 2025 | $889K | +48% |
| Q2 2025 | $892K | +73% |
| Q1 2025 | $865K | +72% |
| Q4 2024 | $35.7M | -82% |
CRSP's revenue is recovering but still below its 2021 peak: $13M last quarter, up 1325% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1026% | +13828 points |
| Q2 2026 | -1152% | +24557 points |
| Q1 2026 | -8933% | +8226 points |
| Q4 2025 | -17913% | -17732 points |
| Q3 2025 | -14855% | +3439 points |
| Q2 2025 | -25709% | +3548 points |
| Q1 2025 | -17159% | +10735 points |
| Q4 2024 | -181% | -216 points |
CRSP's operating margin was −1026% last quarter, up 13828 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CRSP on profitability, with a higher operating margin.
CRSP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$90.1M | -$5.4M |
| Q2 2026 | -$84.1M | +$29.9M |
| Q1 2026 | -$109.4M | -$55.2M |
| Q4 2025 | -$93.1M | -$42.8M |
| Q3 2025 | -$84.7M | +$22.4M |
| Q2 2025 | -$114M | -$17.7M |
| Q1 2025 | -$54.2M | -150% |
| Q4 2024 | -$50.3M | +$46.5M |
CRSP has burned cash in almost every quarter: −$377M over the past year, against −$303M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CRSP on cash generation, producing positive trailing cash flow while its opponent burns cash.
CRSP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +227K shares |
| 1 year | +6% | +5.4M shares |
| 3 years | +22% | +17.3M shares |
| 5 years | +27% | +20.5M shares |
| Available history | +61% | +36.5M shares |
CRSP has 97M diluted shares, up 6% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CRSP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CRSP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2022 | -2.1x | Net Cash |
| Q4 2021 | -2.4x | Net Cash |
| Q3 2021 | -2.4x | Net Cash |
| Q2 2021 | -3.6x | Net Cash |
| Q2 2020 | -329.4x | Net Cash |
| Q1 2020 | -32.3x | Net Cash |
| Q4 2019 | -18.3x | Net Cash |
CRSP has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CRSP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.7 | Neutral |
| Stochastic | 17.4 | Oversold |
CRSP's weekly RSI is 39 (neutral) and its Stochastic is 17 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CRSP PE vs Healthcare Sector
| Metric | CRSP | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CRSP has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CRSP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $50.7 | 16% below |
| 20 week MA | $52.5 | 19% below |
| 50 week MA | $52.7 | 19% below |
| 100 week MA | $50.8 | 16% below |
| 200 week MA | $53.0 | 20% below |
CRSP is in a downtrend: it's below all five of its weekly moving averages, and 20% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CRSP on trend strength, trading above more of its moving averages.
CRSP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66.0 | $168.5 | +155% |
| 2021 | $168.5 | $82.2 | -51% |
| 2022 | $82.2 | $44.1 | -46% |
| 2023 | $44.1 | $62.6 | +42% |
| 2024 | $62.6 | $40.0 | -36% |
| 2025 | $40.0 | $55.1 | +38% |
| 2026 YTD | $55.1 | $42.6 | -23% |
CRSP's yearly returns have swung widely, from +155% in 2020 to −51% in 2021. It's down 23% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CRSP on returns for 2026, with the stronger performance.